Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 4/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 2/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7801433 | 0.93 | PNMT (0.47) | PNMTHTTDRD2DRD4DRD3 | |
| SCHEMBL8471450 | 0.89 | PNMT (0.44) | PNMTHTTDRD2DRD4DRD3 | |
| SCHEMBL28586408 | 0.89 | HTT (0.57) | PNMTHTTDRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL31587774 | 0.88 | PNMT (0.49) | PNMTHTTDRD2DRD4DRD3 | |
| SCHEMBL4663188 | 0.88 | KMT2A (0.46) | PNMTHTTDRD2DRD4DRD3 | |
| SCHEMBL8642710 | 0.88 | KMT2A (0.54) | PNMTHTTDRD2DRD4DRD3 | |
| SCHEMBL7343998 | 0.87 | KMT2A (0.56) | PNMTHTTDRD2DRD4DRD3 | |
| SCHEMBL2565052 | 0.87 | KMT2A (0.56) | PNMTHTTDRD2DRD4DRD3 | |
| SCHEMBL6036900 | 0.87 | PNMT (0.48) | PNMTHTTDRD2DRD4DRD3 | |
| SCHEMBL27963950 | 0.87 | TRPA1 (0.46) | PNMTHTTDRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2264043-B1 | Heterobifunctional pan-selectin inhibitors | GLYCOMIMETICS INC (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20160361332-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS INC (US) | 2016-12-15 | — | — | US | disclosed |
| US-20140178303-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-RE44778-E1 | Heterobifunctional pan-selectin inhibitors | GLYCOMIMETICS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8633303-B2 | Heterobifunctional pan-selectin inhibitors | GLYCOMIMETICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| EP-1934236-B1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS INC (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20120004190-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-7989601-B2 | Heterobifunctional pan-selectin inhibitors | GLYCOMIMETICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| EP-2264043-A1 | Heterobifunctional pan-selectin inhibitors | GlycoMimetics, Inc. (US) | 2010-12-22 | — | — | EP | disclosed |
| US-20100204170-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-7728117-B2 | Heterobifunctional pan-selectin inhibitors | GLYCOMIMETICS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20070054870-A1 | glycomimetics; selectin binding modulators for use in treatment ofinflammatory, autoimmune, infection, cancer, shock, thrombosis, wounds, burns, reperfusion injury, blood, leukocyte-mediated lung injury, spinal cord damage, digestive tract mucous membrane disorders, osteoporosis, arthritis and asthma | GLYCOMIMETICS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004190-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | PNMT 581/4885HTT 4462/4885DRD2 2797/4885 |
| US-20160361332-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | PNMT 581/4885HTT 4462/4885DRD2 2797/4885 |
| US-20070054870-A1 | glycomimetics; selectin binding modulators for use in treatment ofinflammatory, autoimmune, infection, cancer, shock, thrombosis, wounds, burns, reperfusion injury, blood, leukocyte-mediated lung injury, spinal cord damage, digestive tract mucous membrane disorders, osteoporosis, arthritis and asthma | BSG, SELE, SELL | PNMT 2072/4885HTT 4884/4885DRD2 4067/4885 |
| US-20100204170-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | PNMT 581/4885HTT 4462/4885DRD2 2797/4885 |
| US-20140178303-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | PNMT 581/4885HTT 4462/4885DRD2 2797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.